Stegent Equity Advisors Inc. Sells 3,179 Shares of AbbVie Inc. $ABBV

Stegent Equity Advisors Inc. cut its stake in AbbVie Inc. (NYSE:ABBV) by 29.1% during the first quarter, HoldingsChannel reports. The fund owned 7,750 shares of the company’s stock after selling 3,179 shares during the quarter. AbbVie comprises about 1.4% of Stegent Equity Advisors Inc.’s holdings, making the stock its 23rd largest position. Stegent Equity Advisors Inc.’s holdings in AbbVie were worth $1,686,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Chelsea Counsel Co. bought a new stake in AbbVie during the third quarter valued at about $26,000. Litman Gregory Wealth Management LLC bought a new position in AbbVie in the fourth quarter worth about $28,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at about $29,000. Imprint Wealth LLC boosted its holdings in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares in the last quarter. Finally, Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie in the 3rd quarter valued at about $31,000. 70.23% of the stock is owned by institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ABBV shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Canaccord Genuity Group boosted their target price on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Tuesday, June 23rd. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Evercore set a $235.00 price target on AbbVie in a report on Friday, May 15th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie Trading Down 0.2%

NYSE:ABBV opened at $251.07 on Thursday. The company has a market capitalization of $443.59 billion, a P/E ratio of 123.68, a PEG ratio of 0.83 and a beta of 0.32. AbbVie Inc. has a 12 month low of $184.63 and a 12 month high of $255.99. The firm has a fifty day simple moving average of $217.86 and a 200-day simple moving average of $219.76.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.46 EPS. Equities analysts forecast that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is currently 340.89%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.